Chi-Ping Day, Ph.D.

Chi-Ping  Day, Ph.D.
Staff Scientist

Team Member of:

Dr. Day's research focuses on the development of transgenic and preclinical models of recurrent and metastatic diseases, and identification of therapeutic targets of metastatic melanoma.

Areas of Expertise

metastatic melanoma

Contact Info

Chi-Ping Day, Ph.D.
Center for Cancer Research
National Cancer Institute
Bldg. 37, Room 5046
Bethesda, MD 20892-4264
Ph: 240-760-6905

Dr. Day's expertise is in cancer modeling and translation of preclinical testing to clinics, focusing on immunotherapies and its combinations with other treatment. His researches emphasize the modeling as an approach to map the complex system through a process of continuous improvement. He also have many years of experience in building the infrastructure of research, facilitating the efficiency, proficiency, and productivity of a lab under appropriate budget control.  

Inventions 1. Lentiviral vectors for long term in vivo expression of dual fluorescence/luminescence reporters. (2011) Inventors: Dominic Esposito, Chi-Ping Day, and Glenn Merlino. NIH Employee Invention Report Reference No. E‐132‐2011. 2. A bioimaging marker‐tolerant mouse allowing consistent tumor labeling and monitoring in an immunocompetent mouse model. (2010) Inventors: Chi-Ping Day and Glenn Merlino. NIH Employee Invention Report Reference No. E‐173‐2010.

NIH Scientific Focus Areas:
Cancer Biology, Immunology

Selected Publications

  1. Day CP, Marchalik R, Merlino G, Michael H
    Laboratory Investigation. (Accepted): 2017. [ Journal Article ]
  2. Melanoblast transcriptome analysis reveals novel pathways promoting melanoma metastasis..
    Marie KL, Sassano A, Yang HH, Michalowski AM, Michael HT, Guo T, Tsai YC, Weissman AM, Lee MP, Jenkins LM, Zaidi MR, Pérez-Guijarro E, Day CP, Arnheiter H, Davis S, Meltzer PS, Merlino G, Mishra PJ.
    Nature Communication. (In Press), 2020. [ Journal Article ]
  3. Thomas RM, Van Dyke T, Merlino G, Day CP
    Cancer Research. 76(20): AACR 5921-5925, 2016. [ Journal Article ]
  4. Day CP, Merlino G, Van Dyke T.
    Cell. 163 (1): 39-53, 2015. [ Journal Article ]
  5. Day CP, Carter J, Weaver Ohler Z, Bonomi C, El Meskini R, Martin P, Graff-Cherry C, Feigenbaum L, Tüting T, Van Dyke T, Hollingshead M, Merlino G.
    PLoS One. 9 (11): e109956., 2014. [ Journal Article ]

Dr. Chi-Ping Day received his BS diploma in chemistry from National Cheng-Kung University, Tainan, Taiwan in 1992 and MS diploma in biochemistry from National Yang-Ming University, Taipei, Taiwan in 1996. He then joined the Graduate School of Biomedical Sciences at the University of Texas Health Science Center at Houston and M. D. Anderson Cancer Center, where he received his Ph.D. in 2005 for his work on the development of breast cancer-specific gene therapy system. In October 2005, he joined the laboratory of Dr. Merlino as a visiting fellow to receive his post-doctoral training, then became Staff Scientist in 2012.

By Peter Kelmenson, Technical Information Scientist
New Breed of Mice May Improve Accuracy for Preclinical Testing of Cancer Drugs
FREDERICK, MD — May 6, 2015
Glowing mice with working immune systems make for better cancer models say scientists
By Anthony King, 19-Jun-2015